Rhapsido (remibrutinib) - Novartis
lirentelimab (AK002) - Allakos
Xolair (omalizumab) - Roche, Novartis
Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen
Omlyclo (omalizumab-igec) - Celltrion
Nucala (mepolizumab) - GSK
fenebrutinib (RG7845) - Roche
barzolvolimab (CDX-0159) - Celldex
THB001 - Third Harmonic Bio
Fasenra (benralizumab) - AstraZeneca
Dupixent (dupilumab) - Sanofi, Regeneron
AK006 - Allakos
http://www.ncbi.nlm.nih.gov/pubmed/41654334
 
Florence Ida Hsu; Jonathan A Bernstein; Krishan D Chhiba; Sarbjit S Saini
 
Feb 8, 2026
 
Next